Navigation Links
Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound
Date:6/15/2010

FREISING-WEIHENSTEPHAN, Germany, June 15, 2010 /PRNewswire/ -- Pieris AG announced today the initiation of a Phase I clinical trial in cancer patients for its lead program, PRS-050, an anti-VEGF Anticalin. The trial is an open-label, dose-escalating evaluation of the compound's safety and tolerability in patients with solid tumors. Conducted at three sites in Germany, the trial is underway and patients from the first cohort have been dosed.

"Meeting our goal of initiating this trial in the first half of 2010 demonstrates Pieris' commitment to establishing the safety and the therapeutic relevance of the Anticalin drug class," stated Stephen Yoder, CEO of Pieris. "Further, the high potency observed in preclinical studies, together with the small size and the lack of an antibody Fc domain, show promise of an attractive combined efficacy and safety profile for PRS-050."

The trial is designed to test PRS-050 in approximately 40 patients, who will receive the compound and then be monitored for safety and tolerability. The patients recruited for the trial are cancer patients with advanced, recurrent or metastatic solid tumors, refractory to standard therapy.

PRS-050 is an anti-VEGF (Vascular Endothelial Growth Factor) Anticalin discovered and developed internally at the company from Pieris' proprietary Anticalin libraries. PRS-050's mechanism of action is based on its ability to bind the VEGF ligand, thereby inhibiting tumor growth. VEGF's role in cancer angiogenesis, the mechanism by which cancer tumors increase blood vessel development to deliver key nutrients and oxygen is well established, both scientifically and clinically.

About Pieris


'/>"/>
SOURCE Pieris AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Pieris Announces Positive Preclinical Data on c-Met Anticalin Drug Program
2. Pieris Reports Preclinical Development Progress of its Next Generation VEGF Antagonist
3. Pieris AG Enters into Anticalin Collaboration With Allergan, Inc.
4. Pieris Raises EUR 25 M (US$ 38 M) in Series B Financing Round
5. Pieris Validates the Use of Anticalins(R) as Ophthalmologic Biotherapeutics
6. Onyx Pharmaceuticals Initiates Phase 1 Study of Oral Proteasome Inhibitor in Advanced Solid Tumors
7. NewLink Initiates Pivotal Phase 3 Clinical Trial of HyperAcute(R)-Pancreas Immunotherapy for Resected Pancreatic Cancer
8. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-111 and Herceptin in Patients with Advanced Her2 Positive Breast Cancer
9. Fibrocell Science, Inc. Initiates Histology Study of azficel-T
10. Chimerix Initiates Phase 1 Study of CMX157
11. Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 The Pittcon Organizing Committee ... Food Safety Tech , an e-Journal and producer of ... agreement for the second year for the co-location of Food ... The partnership provides that the registration fee to attend the ...
(Date:1/15/2014)... California , January 15, 2014 Oxford ... today announced the appointment of Thomas C Reynolds MD, PhD ... years, development experience gained in the biotechnology industry, most recently ... am delighted to welcome Tom at this transformative time for ...
(Date:1/15/2014)... 15, 2014 More than 5 million ... 1 in 3 seniors will die with Alzheimer’s or ... jaw-dropping figures have shocked many Americans into looking for ... prevent these tragic age-related cognitive disorders. Jonathan Weisman, president ...
(Date:1/15/2014)... 2013 was a banner year of continued innovation ... continued independent research led by the team at Wake ... million grant from the Susanne Marcus Collins Foundation, had ... reviewed journal, Amy Grant highlighted Brainwave Optimization® in First ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3
... , , OMAHA, Neb., Aug. 12 Transgenomic Inc. (OTC Bulletin ... Transgenomic Inc. Second Quarter 2009 Earnings Release, ... Wednesday, August 12, 2009 @ 5:00 p.m. Eastern, Where: http://www.transgenomic.com/events.asp?id=6 , ... to the web at the, ...
... , SAN DIEGO, Aug. 12 Imagenetix, ... second study conducted on its proprietary compound, 1-TDC, for the treatment ... University, Department of Periodontology and Oral Biology, led the investigative team. ... of Periodontology and is also available online at: ...
... ATLANTA, Aug. 12 CryoLife, Inc., (NYSE: ... cardiovascular tissue processing company, today announced that it has ... Administration (FDA) for its CryoPatch((R)) SG pulmonary human cardiac ... SynerGraft technology designed to remove allogeneic donor cells and ...
Cached Biology Technology:Reminder: Transgenomic Inc. Announces Second Quarter 2009 Earnings Release Conference Call Webcast 2Boston University Periodontal Study on Imagenetix Compound Published in The Journal of Periodontology 2Boston University Periodontal Study on Imagenetix Compound Published in The Journal of Periodontology 3CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Cardiac Patch Material 2CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Cardiac Patch Material 3CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Cardiac Patch Material 4
(Date:4/18/2014)... Ill. For the past 20 years, researchers have ... the research findings have suggested that soil organic carbon ... conventional tillage systems to no-till systems. However, there is ... systems in corn and soybean rotations without cover crops, ... organic carbon stocks at the published rates. , "Some ...
(Date:4/18/2014)... University] Asteroid and comet impacts can cause widespread ... or even global scales. But new research from Brown ... of ancient life at the time of an impact. ... Schultz has found fragments of leaves and preserved organic ... impacts in Argentina. The material could provide a snapshot ...
(Date:4/17/2014)... drug under clinical trials to treat tuberculosis could be ... act against various bacteria, fungal infections and parasites, yet ... Illinois chemists and collaborators. , Led by U. of ... different ways the drug SQ109 attacks the tuberculosis bacterium, ... pathogens from yeast to malaria and how targeting ...
Breaking Biology News(10 mins):Researchers question published no-till soil organic carbon sequestration rates 2Researchers question published no-till soil organic carbon sequestration rates 3Researchers question published no-till soil organic carbon sequestration rates 4Impact glass stores biodata for millions of years 2Impact glass stores biodata for millions of years 3Multitarget TB drug could treat other diseases, evade resistance 2
... In the waters along Florida,s east and west coasts, ... on the once severely overfished Atlantic goliath grouper, a ... southeastern United States after a 21-year moratorium on its ... world. The three-year study will determine what specific ...
... A new research program funded by the National ... changing climate has on human health. Led by NIH,s ... will research the risk factors that make people more ... environmental exposures, such as air pollution and toxic chemicals; ...
... iPhone app that measures the user,s heart rate is not ... idea for a Worcester Polytechnic Institute (WPI) researcher who is ... medical monitors able to capture and transmit vital physiological data. ... of biomedical engineering at WPI, has developed a smart phone ...
Cached Biology News:FSU biologists fish for reasons behind endangered grouper's comeback 2FSU biologists fish for reasons behind endangered grouper's comeback 3NIH launches research program to explore health effects from climate change 2NIH launches research program to explore health effects from climate change 3Hold the phone for vital signs 2
... Advance 9.1 is the ... integrated application for desktop ... biology data management available. ... for export. Robust on-board ...
Borosilicate Glass. Certified for use with the Beacon 2000 Systems, 1,000 tubes/case...
Borosilicate Glass. Certified for use with the Beacon 2000 Systems, 1,000 tubes/case...
... Engineered with new technology incorporating ... for unsurpassed flexibility, the new Varian ... advanced spectrometer available today., ,The Varian ... each transmitter and receiver channel, providing ...
Biology Products: